MP15-19 COLLAGENASE CLOSTRIDIUM HISTOLYTICUM FOR TREATMENT OF URETHRAL STRICTURE DISEASE IN A RAT MODEL OF URETHRAL FIBROSIS

Abstract

You have accessJournal of UrologyTrauma/Reconstruction: Urethral Reconstruction (including Stricture) I1 Apr 2015MP15-19 COLLAGENASE CLOSTRIDIUM HISTOLYTICUM FOR TREATMENT OF URETHRAL STRICTURE DISEASE IN A RAT MODEL OF URETHRAL FIBROSIS Premsant Sangkum, Hogyoung Kim, Mostafa Bouljihad, Manish Ranjan, Amrita Datta, Sree Mandava, Faysal Yafi, Suresh Sikka, Asim Abdel-Mageed, and Wayne Hellstrom Premsant SangkumPremsant Sangkum More articles by this author , Hogyoung KimHogyoung Kim More articles by this author , Mostafa BouljihadMostafa Bouljihad More articles by this author , Manish RanjanManish Ranjan More articles by this author , Amrita DattaAmrita Datta More articles by this author , Sree MandavaSree Mandava More articles by this author , Faysal YafiFaysal Yafi More articles by this author , Suresh SikkaSuresh Sikka More articles by this author , Asim Abdel-MageedAsim Abdel-Mageed More articles by this author , and Wayne HellstromWayne Hellstrom More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.902AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Collagenase clostridium histolyticum (CCH) has been recently FDA-approved for minimally invasive treatment of Peyronie's disease (PD). PD is a fibrotic wound-healing disorder of the tunica albuginea of the corpus cavernosum. Urethral stricture is a scarring process involving the urethral mucosa and surrounding spongy tissue of the corpus spongiosum. Increases in collagen type I and III have been documented in both conditions. We, therefore, postulate that CCH may effectively treat urethral stricture fibrosis. This is a proof of concept study using CCH for the treatment of urethral fibrosis in a rat model. METHODS Male Sprague-Dawley rats (n=24, 300–350 g) were anesthetized with 100/10 ml/kg ketamine/xylazine intraperitoneally. Urethral fibrosis was induced by TGF-β1 injection into two places of the urethra via a small penoscrotal incision. Two weeks following TGF-β1 injection, different groups were injected with 0.05 mg CCH or calcium chloride vehicle into the same area of the urethra. The rats were sacrificed at two weeks following the CCH or vehicle injection. The urethral tissues were harvested and evaluated by Hematoxilin & Eosin (H&E) and Masson trichrome staining by a single, blinded pathologist. RESULTS Histological assessment of urethral sections (H&E and Masson's trichrome stain, x400) demonstrated a normal urethral lumen surrounded by normal distribution of collagen bundles and smooth muscle cells without fibrosis in the sham group, and moderate fibrosis with densely packed collagenous stroma involving the submucosal tissues in the stricture groups. There was minimal submucosal fibrosis with a moderate amount of smooth muscle cells in the vehicle and CCH injection groups (Fig. 1). There were no complications from the CCH injection. CONCLUSIONS CCH is contraindicated in ventral plaque PD patients due to concerns of urethral complications. Our study shows that CCH was safe for urethral injection and may have a role in the treatment of urethral stricture disease. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e166 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Premsant Sangkum More articles by this author Hogyoung Kim More articles by this author Mostafa Bouljihad More articles by this author Manish Ranjan More articles by this author Amrita Datta More articles by this author Sree Mandava More articles by this author Faysal Yafi More articles by this author Suresh Sikka More articles by this author Asim Abdel-Mageed More articles by this author Wayne Hellstrom More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...